Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

RCT (n=120) found anthracycline-containing adjuvant therapy linked to decline in LVEF during extended follow-up, and neither candesartan nor metoprolol prevented reduction in LVEF at 2 years, suggesting cardioprotective approach may not be required in most patients without CVD.

Source:

Circulation